1513.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 01:20):

Stats
Today's Volume	259 312
Average Volume	657 870
Market Cap	33.29B
EPS	HKD0.500 ( 2023-10-24 )
Last Dividend	HKD1.744 ( 2023-07-04 )
Next Dividend	HKD0 ( N/A )
P/E	11.41
ATR14	HKD0.0310 (0.12%)

Volume Correlation

Long: 0.47 (neutral)

Short: -0.53 (weak negative)

Signal:(51.426) Neutral

Livzon Pharmaceutical Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Livzon Pharmaceutical Correlation - Currency/Commodity

0.19
( neutral )

0.12
( neutral )

0.00
( neutral )

0.33
( neutral )

0.31
( neutral )

0.07
( neutral )

Livzon Pharmaceutical Financials

Annual	2023
Revenue:	HKD12.43B
Gross Profit:	HKD7.96B (64.08 %)
EPS:	HKD2.10

Q4	2023
Revenue:	HKD2.78B
Gross Profit:	HKD1.79B (64.59 %)
EPS:	HKD0.380

Q3	2023
Revenue:	HKD2.96B
Gross Profit:	HKD1.88B (63.57 %)
EPS:	HKD0.500

Q2	2023
Revenue:	HKD3.28B
Gross Profit:	HKD2.13B (65.15 %)
EPS:	HKD0.590

Financial Reports:

No articles found.

Livzon Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD1.744 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Livzon Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (99.98%) | Divividend Growth Potential Score: 6.64 - Stable (32.71%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.221	2014-07-08
Last Dividend	HKD1.744	2023-07-04
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	HKD9.31	--
Avg. Dividend % Per Year	0.00%	--
Score	3.1	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.64
Div. Directional Score	8.32	--

Next Divdend (Est)
(2024-06-24)

HKD1.912 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.10

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2382.HK	Ex Dividend Junior	2023-05-30	Annually	0.00%
1373.HK	Ex Dividend Knight	2023-10-04	Semi-Annually	0.00%
0435.HK	Ex Dividend Knight	2023-09-21	Semi-Annually	0.00%
6811.HK	Ex Dividend Knight	2023-10-05	Semi-Annually	0.00%
1919.HK	Ex Dividend Knight	2023-05-30	Sporadic	0.00%
0952.HK	Ex Dividend Junior	2023-09-14	Sporadic	0.00%
0083.HK	Ex Dividend Knight	2023-10-27	Semi-Annually	0.00%
3300.HK	No Dividend Player	2023-08-02	Sporadic	0.00%
1516.HK	Ex Dividend Junior	2023-09-27	Annually	0.00%
0564.HK	Ex Dividend Knight	2023-06-07	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.157	1.500	6.86	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0780	1.200	7.40	8.88	[0 - 0.3]
returnOnEquityTTM	0.141	1.500	9.54	10.00	[0.1 - 1]
payoutRatioTTM	0.814	-1.000	1.864	-1.864	[0 - 1]
currentRatioTTM	2.14	0.800	4.32	3.46	[1 - 3]
quickRatioTTM	1.874	0.800	3.68	2.95	[0.8 - 2.5]
cashRatioTTM	1.400	1.500	3.33	5.00	[0.2 - 2]
debtRatioTTM	0.165	-1.500	7.24	-10.00	[0 - 0.6]
interestCoverageTTM	23.66	1.000	2.35	2.35	[3 - 30]
operatingCashFlowPerShareTTM	3.81	2.00	8.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.92	2.00	8.54	10.00	[0 - 20]
debtEquityRatioTTM	0.295	-1.500	8.82	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.641	1.000	2.65	2.65	[0.2 - 0.8]
operatingProfitMarginTTM	0.194	1.000	8.11	8.11	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.853	1.000	6.37	6.37	[0.2 - 2]
assetTurnoverTTM	0.496	0.800	-0.0246	-0.0197	[0.5 - 2]
Total Score				10.00

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.51	1.000	8.94	0	[1 - 100]
returnOnEquityTTM	0.141	2.50	9.71	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.92	2.00	9.03	10.00	[0 - 30]
dividendYielPercentageTTM	7.19	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.81	2.00	8.73	10.00	[0 - 30]
payoutRatioTTM	0.814	1.500	1.864	-1.864	[0 - 1]
pegRatioTTM	1.078	1.500	6.15	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.284	1.000	5.40	0	[0.1 - 0.5]
Total Score				6.64

Livzon Pharmaceutical

Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.